Press release
EADV 2020: Lilly and Incyte Showcase New Data for Baricitinib for the Treatment of Moderate to Severe Atopic Dermatitis
- Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial - Baricitinib was recently approved by the European
About this update from Incyte Corporation
[{"type":"text","content":"- Latest baricitinib data highlight long-term efficacy and safety results from BREEZE-AD3 trial\n - Baricitinib was recently approved by the European Commission, representing the first global approval for the medicine in atopic dermatitis\n\n\nINDIANAPOLIS, Oct. 31, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib will be presented at the 29th annual European Academy of Dermatology and Venereology (EADV) Congress taking place virtually October 29-31, 2020. The data reinforce Lilly's commitment to developing medicines for the treatment of dermatologic diseases such as moderate to severe atopic dermatitis (AD). AD—also known as eczema—is a chronic inflammatory skin disorder that causes intense skin itching, redness, rash and sores. \nAt this year's virtual EADV meeting, data from BREEZE-AD3, a Phase 3 study evaluating the long-term efficacy and safety of baricitinib in adult patients with moderate to severe AD will be shared. In the study, responders as assessed by the validated Investigator Global Assessment score of \"clear or almost clear\" skin (vIGA 0,1) and partial responders (vIGA 2) from one of the 16-week originating studies entered and continued treatment with baricitinib 2-mg or 4-mg once daily for an additional 52 weeks. At the start of BREEZE-AD3 (after 16 weeks of treatment in the originating studies), 45.7% of responders and partial responders on 4-mg of baricitinib had a vIGA-AD score of 0 or 1, while 40% had a vIGA-AD score of 0 or 1 after 68 weeks of continuous therapy. Similarly, at the start of BREEZE-AD3 46.3% of responders and partial responders on 2-mg of baricitinib had a vIGA-AD score of 0 or 1, while 50% had a vIGA-AD score of 0 or 1 after 68 weeks of continuous therapy. These results indicate that baricitinib 4-mg and 2-mg dose groups were able to maintain clear or almost clear skin response rates through the 68-week treatment period. The safety profile in this study was consistent with the known safety findings of baricitinib in previous 16-week, placebo-controlled AD studies. \n\"Baricitinib is part of a class of oral medicines called JAK inhibitors. These data support its potential use as a treatment for adults with moderate to severe AD,\" said Jonathan Silverberg, director of clinical research at The George Washington Universit...